Pumitamig用于肾细胞癌的I 期 / II 期研究｜NCT07293351

一分钟看懂

这是一项关于肾细胞癌的I 期 / II 期研究，登记的药物或干预包括Pumitamig；Ipilimumab；Cabozantinib；Casdatifan，当前状态为招募中。登记地点显示中国北京、广州、天津、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Pumitamig；Ipilimumab；Cabozantinib；Casdatifan · I 期 / II 期

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

* Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not amenable to curative surgery or radiation therapy) or metastatic Renal Cell Carcinoma (RCC).
* Participants must have clear cell RCC (ccRCC) or non-clear cell RCC (nccRCC) may be enrolled in Part 1. Note: Part 2 may only enroll participants with ccRCC.
* Participants may have favorable, intermediate or poor risk disease categories.
* Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:
i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last
ii) For Part 1A participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received any therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., ipilimumab).
iii) For Part 1B participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with cabozantinib.
iv) For Parts 2D and 2E: Prior treatment with a HIF-2α inhibitor or other agent that targets the HIF-2α pathway is not allowed.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT07293351；登记信息更新于 2026-09-14。